Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma PDF Download

Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma PDF full book. Access full book title Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma by Richard J. Buka. Download full books in PDF and EPUB format.

Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma

Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma PDF Author: Richard J. Buka
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318070246
Category : Medical
Languages : en
Pages : 95

Book Description
Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: • DLBCL: an overview • CAR T cells • CAR T-cell products • Delivering CAR T-cell therapy and managing patient expectations • CAR T-cell therapy-related toxicities

Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma

Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma PDF Author: Richard J. Buka
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318070246
Category : Medical
Languages : en
Pages : 95

Book Description
Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: • DLBCL: an overview • CAR T cells • CAR T-cell products • Delivering CAR T-cell therapy and managing patient expectations • CAR T-cell therapy-related toxicities

Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma

Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma PDF Author: R.J. Buka
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318069353
Category : Medical
Languages : en
Pages : 95

Book Description
Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: • DLBCL: an overview • CAR T cells • CAR T-cell products • Delivering CAR T-cell therapy and managing patient expectations • CAR T-cell therapy-related toxicities

Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book

Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book PDF Author: Daniel W. Lee
Publisher: Elsevier Health Sciences
ISBN: 0323755976
Category : Medical
Languages : en
Pages : 246

Book Description
From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Fast Facts: CAR T-Cell Therapy

Fast Facts: CAR T-Cell Therapy PDF Author: Richard J. Buka
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318067415
Category : Medical
Languages : en
Pages : 71

Book Description
Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field. Table of Contents: • CAR T cells • Clinical application • Practical aspects • Future directions

Fast Facts: Lymphoma

Fast Facts: Lymphoma PDF Author: Graham P. Collins
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318072869
Category : Medical
Languages : en
Pages : 188

Book Description
Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.

Blood and Marrow Transplant Handbook

Blood and Marrow Transplant Handbook PDF Author: Richard T. Maziarz
Publisher: Springer
ISBN: 3319138324
Category : Medical
Languages : en
Pages : 437

Book Description
This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees.

Fast Facts: Immuno-Oncology

Fast Facts: Immuno-Oncology PDF Author: S. Clarke
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318068225
Category : Medical
Languages : en
Pages : 128

Book Description
The treatment of cancer has been revolutionized by therapies that modulate the immune system, with benefits for quality of life and survival. Standards of care have changed to reflect developments, but the area is moving fast. Keeping abreast of new therapies and trial data can be challenging. This second edition of 'Fast Facts: Immuno-Oncology' takes you from the fundamentals of immunology through to the new concepts of immunoediting and immunotherapy and likely future directions. Whether you have worked in oncology for decades and need a refresher or you are just starting out and need a crash course, this book provides all you need to know about immuno-oncology, concisely summarized. Table of Contents: • Components of the immune system • How cancers evade the immune system • How cancer immunotherapy works • Clinical use of immune checkpoint inhibitors • The future of immuno-oncology

Fast Facts: Gene Therapy

Fast Facts: Gene Therapy PDF Author: R. Herzog
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318066672
Category : Medical
Languages : en
Pages : 102

Book Description
Gene therapy has emerged as a discipline in medicine that can provide treatments for diseases that have no other therapies available, save lives of patients for whom there is no other hope and replace suboptimal treatments with lasting cures. 'Fast Facts: Gene Therapy' provides an overview of the field, looking at the main vector systems used to transfer the therapeutic gene constructs, the molecular mechanisms and the history of gene therapy, as well as the safety and ethical considerations of this important advance. Multiple examples of diseases that are already successfully treated with gene therapy are given, with discussion of treatments that hold promise for the future. This book will be informative and of value to health professionals, researchers, students and anyone with an interest in this exciting and fast-moving area. Contents: • Principles of gene therapy • Gene therapy techniques • Ethical and safety considerations • Gene therapies with proven clinical efficacy • Genome editing • Research directions – the next wave of treatments

The EBMT/EHA CAR-T Cell Handbook

The EBMT/EHA CAR-T Cell Handbook PDF Author: Nicolaus Kröger
Publisher: Springer Nature
ISBN: 3030943534
Category : Medical
Languages : en
Pages : 221

Book Description
This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.

Cancer Immunology and Immunotherapy

Cancer Immunology and Immunotherapy PDF Author: Mansoor M. Amiji
Publisher: Academic Press
ISBN: 012823637X
Category : Medical
Languages : en
Pages : 550

Book Description
Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO